Finance

Lists
Why is 300204 down 2,63%?
Dive Deeper
300204:SHE
Staidson (Beijing) BioPharmcutcls Co Ltd
CN¥19,27
-2,63%
(-0,52) 1D
15 Okt., 15:04:16 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 300204...
Open
CN¥19,20
High
CN¥20,23
Low
CN¥19,03
Mkt. cap
10,72 mjd
Avg. vol.
13,80 m
Volume
12,40 m
52-wk high
CN¥42,65
52-wk low
CN¥18,98
EPS
-CN¥0,19
Shares outstanding
541,34 m
No. of employees
491
Open
CN¥19,20
High
CN¥20,23
Low
CN¥19,03
Mkt. cap
10,72 mjd
Avg. vol.
13,80 m
Volume
12,40 m
52-wk high
CN¥42,65
52-wk low
CN¥18,98
EPS
-CN¥0,19
Shares outstanding
541,34 m
No. of employees
491
News stories
From web sources and news partners
About Staidson (Beijing) BioPharmcutcls Co Ltd
CEO-
Employees491
Founded16 Aug. 2002
Headquarters-
Sector-
Websitestaidson.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
54,94 m
39,69 m
46,90 m
46,00 m
Cost of goods sold
11,23 m
11,32 m
10,23 m
14,61 m
Cost of revenue
11,23 m
11,32 m
10,23 m
14,61 m
Research and development expenses
11,77 m
26,83 m
12,21 m
17,66 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35,82 m
47,90 m
29,37 m
39,45 m
Operating expense
49,02 m
74,75 m
42,24 m
58,51 m
Total operating expenses
60,25 m
86,07 m
52,47 m
73,11 m
Operating income
-5,31 m
-46,38 m
-5,57 m
-27,11 m
Other non operating income
11,61 k
-92,37 k
-220,74 k
210,84 k
EBT including unusual items
-8,64 m
-50,52 m
-9,28 m
-29,58 m
EBT excluding unusual items
-9,39 m
-49,70 m
-8,89 m
-30,77 m
Income tax expense
1,94 k
-296,49 k
-1,49 k
1,56 k
Effective tax rate
-0,02%
0,59%
0,02%
-0,01%
Other operating expenses
1,35 m
176,72 k
603,57 k
1,50 m
Net income
-6,05 m
-47,07 m
-8,43 m
-28,34 m
Net profit margin
-11,02%
-118,59%
-17,98%
-61,60%
Earnings per share
-
-
-
-
Interest and investment income
347,22 k
489,14 k
365,59 k
551,26 k
Interest expense
-4,44 m
-3,45 m
-3,66 m
-3,82 m
Net interest expenses
-4,09 m
-2,96 m
-3,29 m
-3,26 m
Depreciation and amortization charges
-
-
-
-
EBITDA
268,67 k
-40,49 m
317,58 k
-20,45 m
Gain or loss from assets sale
1,11 m
-875,15 k
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme